Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

KYTX

NASDAQ

Kyverna Therapeutics (KYTX)

4.25 USD −2.97% vs prior close Nov 20, 2026
Kyverna Therapeutics, Inc. price graph
11 sessions
5.5 4.0 6 Nov 20 Nov

The line runs 4.88 USD on 6 November through 4.25 USD on 20 November, on a scale from 4.0 to 5.5. Days the market did not trade hold the previous close, flat.

Market cap
268.7M USD
EPS, diluted, year to Dec 2025
−3.64 USD
52-week range
4.25 USD – 12 USD
Avg volume
172.7K
Mentions, 30 days
2

as of Nov 20, 2026

Have Kyverna Therapeutics (KYTX) insiders bought or sold shares recently?

KYTX's newest Form 4 filing is dated 27 May 2026: none in the last 90 days.

Form 4

Have Kyverna Therapeutics (KYTX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
18 Dec 2025SEIDENBERG BETH CDirectorBuy133,3331.0M USD
18 Dec 2025Westlake BioPartners Opportunity Fund I, L.P.10% OwnerBuy133,3331.0M USD
15 Dec 2025Walker Karen MarieChief Technology OfficerSell23,998293K USD
Bought2 open-market purchases266,666$2.00M
Sold1 open-market sale23,998$293K
12 other filings: grants, exercises, tax withholding and transfers, not trades
Have Kyverna Therapeutics (KYTX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
27 May 2026CLARK IAN TDirectorAward5,093
27 May 2026Cohen Fred EDirectorAward5,093
27 May 2026SEIDENBERG BETH CDirectorAward5,093
27 May 2026Shaw ChristiExecutive ChairpersonTax withheld4,19436K USD
27 May 2026Aktar MertDirectorAward5,093
13 Mar 2026GEHCHAN NAJISee RemarksAward18,000
13 Mar 2026GRASSO MARCChief Financial OfficerAward10,000
13 Mar 2026Biddle Warner WestonChief Executive OfficerAward58,000
24 Feb 2026Miller Andrew CraigDirectorAward11,006
24 Feb 2026Emany Sravan KumarDirectorAward11,006
12 Jan 2026Shaw ChristiExecutive ChairpersonAward54,301
15 Dec 2025Walker Karen MarieChief Technology OfficerOption exercise23,998116K USD

Which funds hold Kyverna Therapeutics (KYTX)?

9 of the 45 institutional funds we track reported a Kyverna Therapeutics position for the quarter ended 30 Sep 2026 — a combined 12.3M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Kyverna Therapeutics (KYTX)?
FundPositionSharesValueShares q/q
Millennium ManagementAdded826,1375.6M USD+29.1%
Renaissance TechnologiesHeld (±25%)327,8212.2M USD−1.8%
Point72 Asset ManagementNew position186,9021.3M USD
D. E. Shaw & Co.Trimmed146,890999K USD−68.7%
Citadel AdvisorsHeld (±25%)137,034932K USD−7.2%
Marshall WaceNew position73,276498K USD
Man GroupHeld (±25%)71,918489K USD+4.8%
Two Sigma InvestmentsTrimmed21,575147K USD−58.0%
AQR Capital ManagementNew position16,380111K USD
Balyasny Asset ManagementExited

What has been filed or recorded for Kyverna Therapeutics (KYTX)?

The filings we hold for Kyverna Therapeutics, newest first: 5 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 26 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Kyverna Therapeutics (KYTX)?
And
26 Oct 2026Fails to deliverShares failed to deliver7,241 shares39K USD notional · 0.011% of shares out
19 Oct 2026Fails to deliverShares failed to deliver4,892 shares28K USD notional · 0.008% of shares out
16 Oct 2026Fails to deliverShares failed to deliver9,458 shares56K USD notional · 0.015% of shares out
15 Oct 2026Fails to deliverShares failed to deliver4,660 shares27K USD notional · 0.007% of shares out
13 Oct 2026Fails to deliverShares failed to deliver3,428 shares21K USD notional · 0.005% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.68 USD
30 Sep 2026FinancialsTotal assets189.4M USDat period end
30 Sep 2026FinancialsTotal equity133.2M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.63 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.66 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −3.64 USD
31 Dec 2025FinancialsNet income−161.3M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−3.64 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.85 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.97 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −1.03 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −3.33 USD

What is Reddit saying about Kyverna Therapeutics (KYTX)?

Reddit mentioned KYTX 2 times in the 30 days to 21 November 2026, across 2 of the communities we track. All of them were scored for sentiment: 100% read bullish, 0% bearish and 0% neither. Reddit data updated 21 November 2026.

30-day window, Method

2mentions, 30 days
2communities

How do Reddit mentions of Kyverna Therapeutics (KYTX) compare with its price?

Share ↗
2 mentions

Which subreddits are talking about Kyverna Therapeutics (KYTX)?

30 days

Which subreddits are talking about Kyverna Therapeutics (KYTX)?
CommunityShareMentionsNet sentiment
r/wallstreetbets50%1+0.11
r/stocks50%1+0.13

What do people ask about Kyverna Therapeutics (KYTX)?

From live data
What did Kyverna Therapeutics shares close at?4.25

Kyverna Therapeutics closed at 4.25 USD on 20 Nov 2026, down 2.97% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Kyverna Therapeutics’ market cap?268.7M

Kyverna Therapeutics is worth 268.7M USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.

Have Kyverna Therapeutics insiders bought or sold shares recently?

No Kyverna Therapeutics insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 27 May 2026 (SEC Form 4). See Insiders

Which funds own Kyverna Therapeutics?9 of 45

9 of the 45 funds we track reported a Kyverna Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Renaissance Technologies and Point72 Asset Management. See Funds

When did Kyverna Therapeutics last report earnings?−0.68

Kyverna Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.68 USD; no next date is announced in SEC filings yet. See Filings

What is Reddit saying about Kyverna Therapeutics?0 mentions

Kyverna Therapeutics was mentioned 0 times in the last 7 days across the finance subreddits we track, and 2 times over the trailing 30 days. Of the 2 mentions scored for sentiment, 100% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. RedditReddit ingest across the tracked finance subreddits
  4. SEC EDGARForm 4 filings (insider transactions)
  5. SEC EDGAR13F filings
  6. SECSEC fails-to-deliver (CNS) data
  7. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  8. SEC EDGARreported earnings figures and scheduled report dates
  9. SEC EDGARValuation computed from SEC EDGAR filings
  10. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words